Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cytek Biosciences is a medical devices business based in the US. Cytek Biosciences stocks (CTKB.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.34 – a decrease of 7.13% over the previous week. Cytek Biosciences employs 429 staff and has a trailing 12-month revenue of around $110.4 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$24.11|
|52-week range||$17 - $28.7|
|50-day moving average||$24.1671|
|200-day moving average||$23.493|
|Wall St. target price||$27|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.055|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-09-17)||-7.13%|
|1 month (2021-08-25)||6.21%|
Valuing Cytek Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cytek Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cytek Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 476x. In other words, Cytek Biosciences stocks trade at around 476x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.
However, Cytek Biosciences's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.
Cytek Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$20.2 million.
The EBITDA is a measure of a Cytek Biosciences's overall financial performance and is widely used to measure a its profitability.
To put Cytek Biosciences's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||USD$110.4 million|
|Operating margin TTM||17.69%|
|Gross profit TTM||USD$51.7 million|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$3.5 billion|
TTM: trailing 12 months
There are currently 44,741 Cytek Biosciences stocks held short by investors – that's known as Cytek Biosciences's "short interest". This figure is 51.1% down from 91,557 last month.
There are a few different ways that this level of interest in shorting Cytek Biosciences stocks can be evaluated.
Cytek Biosciences's "short interest ratio" (SIR) is the quantity of Cytek Biosciences stocks currently shorted divided by the average quantity of Cytek Biosciences stocks traded daily (recently around 248561.11111111). Cytek Biosciences's SIR currently stands at 0.18. In other words for every 100,000 Cytek Biosciences stocks traded daily on the market, roughly 180 stocks are currently held short.
To gain some more context, you can compare Cytek Biosciences's short interest ratio against those of similar companies.
However Cytek Biosciences's short interest can also be evaluated against the total number of Cytek Biosciences stocks, or, against the total number of tradable Cytek Biosciences stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytek Biosciences's short interest could be expressed as 0% of the outstanding stocks (for every 100,000 Cytek Biosciences stocks in existence, roughly 0 stocks are currently held short) or 0.0016% of the tradable stocks (for every 100,000 tradable Cytek Biosciences stocks, roughly 2 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Cytek Biosciences.
Find out more about how you can short Cytek Biosciences stock.
We're not expecting Cytek Biosciences to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.
Everything we know about the Gerdau S-A IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
Steps to owning and managing China Evergrande Group shares from Canada.
Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
You must be logged in to post a comment.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.